Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 35 to 85

Using ultrasound to relieve osteoarthritis pain

Official title: Sustained Acoustic Medicine for Osteoarthritis Pain

Run by ZetrOZ, Inc. · NCT05254574 · Data updated 2026-11-12

This study tests whether a continuous ultrasound treatment can help people with mild to moderate osteoarthritis feel less pain and move better compared to a topical pain relief gel.

Quick facts

PhasePhase 1
Study typeInterventional
Ages35 Years to 85 Years
SexAll
Enrollment200 (estimated)
SponsorZetrOZ, Inc.
Industry-sponsored
Drugs / interventionschemotherapy
Locations1 site (Tampa, Florida)
StatusRecruiting
StartedFebruary 14, 2022
Main results expectedMay 1, 2026
Study endsMay 31, 2026
Registry record updatedFebruary 27, 2025
Trial IDNCT05254574 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals aged 35-85 with physician-diagnosed mild to moderate osteoarthritis who experience significant pain affecting their quality of life.

Probably not a fit

Patients with severe osteoarthritis or those who do not meet the specific inclusion criteria may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study compares the effectiveness of Sustained Acoustic Medicine, a continuous ultrasound treatment, to a topical pain relief gel for managing symptoms of osteoarthritis. Participants will be assessed for pain and functional improvement while receiving either treatment. The study focuses on individuals with mild to moderate osteoarthritis in various joints, including the knee and shoulder. The goal is to determine which method provides better relief from pain and enhances quality of life.

Why it matters

Potential benefit: If successful, this treatment could offer a non-invasive and effective alternative for managing osteoarthritis pain.

How similar studies have gone: Other studies using ultrasound for pain management have shown promising results, suggesting potential effectiveness for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Have physician-diagnosed mild to moderate knee, shoulder, elbow, ankle, hip, or spine osteoarthritis OA (OARSI atlas grades 1-2) or also referred to as Degenerative Joint Disease (DJD).
* Fulfill the American College of Rheumatology clinical and radiological diagnostic criteria for knee OA
* Are between 35-85 years of age
* Report a frequent pain score between 3-7 (range: 0-10) during the week preceding enrollment
* Report that knee, shoulder, elbow, ankle, hip, or spine pain negatively affects quality of life
* Are willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved treatment provided to the subject at the initiation of the study
* Are deemed appropriate by their physician or by the study site physician to participate.
* Be willing and able to self-administer treatment daily within their place of residence or during normal daily activity, excluding bathing, showering, or other water activities which may result in submersion of the study device.
* Not use or initiate opioid and/or non-opioid analgesic medications.
* Be willing to discontinue any other interventional treatment modalities on the treatment area during the study period (e.g., transcutaneous electrical nerve stimulation, electronic muscle stimulation, traditional ultrasound).

Exclusion Criteria:

* Cannot successfully demonstrate the ability to put on and take off the device.
* Displays any condition which, in the judgment of the investigator, would make participation in the study unacceptable including, but not limited to, the subject's ability to understand and follow instructions.
* Participated in a clinical trial for an investigational drug and/or agent within 30 days prior to screening.
* Is pregnant.
* Is a prisoner.
* Has a pacemaker.
* Has a malignancy in the treatment area.
* Has an active infection, open sores, or wounds in the treatment area.
* Has impaired sensation in the treatment area, such as caused by chemotherapy or anesthesia.
* Has a known neuropathy (disease of the brain or spinal nerves).
* Has a hereditary disposition (tendency) for excessive bleeding (hemorrhage).
* Have knee, shoulder, elbow, ankle, or hip replacement or other surgical intervention, in the affected area in the past 6 months.
* Requires oxygen support
* Has an allergy to aspirin or other NSAIDs
* Have a secondary cause of arthritis (metabolic or inflammatory)

Where it's running

  • James A Haley Veterans Hospital
    Tampa, Florida, United States
    Recruiting

Study contacts

  • Principal investigator: Sandra Winkler, Ph.D. — James A. Haley Veterans Hospital
  • Study coordinator: George K. Lewis, Ph.D.
  • Email: george@zetroz.com
  • Phone: 888-202-9831

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.